Calithera Biosciences Inc. (NASDAQ:CALA) shares were down 1.9% during trading on Friday . The company traded as low as $3.02 and last traded at $3.14, with a volume of 121,706 shares trading hands. The stock had previously closed at $3.20.

A number of research analysts have commented on CALA shares. Wells Fargo & Co. reiterated a “buy” rating on shares of Calithera Biosciences in a research report on Thursday, May 12th. JMP Securities reissued a “buy” rating on shares of Calithera Biosciences in a research note on Wednesday, June 8th. Finally, Zacks Investment Research downgraded Calithera Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, May 17th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Calithera Biosciences presently has a consensus rating of “Buy” and an average target price of $10.38.

The company has a 50 day moving average of $3.76 and a 200 day moving average of $4.99. The firm’s market cap is $60.09 million.

Calithera Biosciences (NASDAQ:CALA) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.47) by $0.05. On average, analysts expect that Calithera Biosciences Inc. will post ($2.15) earnings per share for the current fiscal year.

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.